ImmunoBrain presents Phase 1b data for immune checkpoint therapy
ImmunoBrain has unveiled promising Phase 1b results for its anti-PD-L1 therapy, IBC-Ab002, targeting early Alzheimer’s disease during the AD/PD 2026 conference in Copenhagen. The IBC-01-01 trial, which involved 40 patients across the U.K., Netherlands, and Israel, focused on assessing safety, tolerability, and pharmacokinetics, alongside exploratory cerebrospinal fluid (CSF) biomarker analyses at the 12-month mark.
These findings are significant for the longevity and healthspan field, as they suggest that IBC-Ab002 may offer a novel approach to enhancing adaptive immunity without the typical risks associated with chronic PD-1/PD-L1 blockade. The trial reported manageable immune-related adverse events and encouraging trends in CSF biomarkers like neurogranin and total-Tau, hinting at potential synaptic and neuronal protection.
As ImmunoBrain prepares to advance to the next clinical phase, which will incorporate cognitive endpoints, this research could pave the way for innovative therapeutic strategies in Alzheimer’s treatment. For a deeper dive into these findings, I highly recommend reading the full article.